Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company focused on developing therapeutics to modify the course of cardiopulmonary diseases, particularly pulmonary arterial hypertension (PAH). The company's website is located at https://www.inhibikase.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Inhibikase Therapeutics, Inc. does
In the company’s own words
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company focused on developing therapeutics to modify the course of cardiopulmonary diseases, particularly pulmonary arterial hypertension (PAH). The company's website is located at https://www.inhibikase.com.
The company's lead product candidate is IKT-001, a novel oral prodrug of imatinib mesylate designed to treat PAH, a rare, progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance affecting approximately 50,000 Americans. IKT-001 emerged from Inhibikase's medicinal chemistry program targeting type III receptor tyrosine kinases, including platelet-derived growth factor receptors and c-Kit. The prodrug formulation was designed to reduce gastrointestinal side effects commonly associated with imatinib while maintaining therapeutic efficacy. The company has completed bioequivalence studies in healthy volunteers and initiated a Phase 3 adaptive clinical trial called IMPROVE-PAH, which comprises two parts evaluating approximately 486 patients across approximately 180 global sites.
Inhibikase commenced operations in September 2008 as a Georgia limited liability company initially focused on protein kinase inhibitors for bacterial and viral infectious diseases. The company expanded into neurodegeneration and brain diseases before shifting its strategic focus toward PAH. The company completed an initial public offering in 2020 and began trading on Nasdaq under the ticker IKT.
Recent significant corporate actions include the February 2025 acquisition of CorHepta Pharmaceuticals, Inc. for $15 million in stock consideration to expand the product pipeline and strengthen scientific leadership. In May 2025, the company licensed risvodetinib globally to ABLi Therapeutics, retaining eligibility for development and regulatory milestone payments up to $47.5 million plus double-digit royalties on net sales. In November 2025, Inhibikase completed an underwritten public offering raising $115 million in gross proceeds.
The company holds global commercialization rights to IKT-001 with U.S. patent protection extending until 2039, with potential extension to 2044 through pending patent applications. The PAH market was valued at approximately $8.3 billion in 2025 and is projected to grow at a compound annual growth rate of 3.3% through 2034. Inhibikase does not currently own manufacturing facilities and relies on third-party contract development and manufacturing organizations for preclinical and clinical drug supply.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- WILMINGTON, DE
- Fiscal year end
- December
- CIK
- 1750149
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Inhibikase Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Inhibikase Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Inhibikase Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Inhibikase Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Inhibikase Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”